Inhibition of cytochrome P450 3A by acetoxylated analogues of resveratrol in in vitro and in silico models

被引:14
作者
Basheer, Loai [1 ]
Schultz, Keren [1 ]
Kerem, Zohar [1 ]
机构
[1] Hebrew Univ Jerusalem, Robert H Smith Fac Agr Food & Environm, Inst Biochem Food Sci & Nutr, POB 12, IL-76100 Rehovot, Israel
来源
SCIENTIFIC REPORTS | 2016年 / 6卷
关键词
HERB-DRUG INTERACTION; P450-MEDIATED METABOLISM; STRUCTURAL BASIS; CYP3A4; RAT; MECHANISM; TRANSPORT; ENZYMES; LIVER; BIOAVAILABILITY;
D O I
10.1038/srep31557
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Many dietary compounds, including resveratrol, are potent inhibitors of CYP3A4. Here we examined the potential to predict inhibition capacity of dietary polyphenolics using an in silico and in vitro approaches and synthetic model compounds. Mono, di, and tri-acetoxy resveratrol were synthesized, a cell line of human intestine origin and microsomes from rat liver served to determine their in vitro inhibition of CYP3A4, and compared to that of resveratrol. Docking simulation served to predict the affinity of the synthetic model compounds to the enzyme. Modelling of the enzyme's binding site revealed three types of interaction: hydrophobic, electrostatic and H-bonding. The simulation revealed that each of the examined acetylations of resveratrol led to the loss of important interactions of all types. Triacetoxy resveratrol was the weakest inhibitor in vitro despite being the more lipophilic and having the highest affinity for the binding site. The simulation demonstrated exclusion of all interactions between tri-acetoxy resveratrol and the heme due to distal binding, highlighting the complexity of the CYP3A4 binding site, which may allow simultaneous accommodation of two molecules. Finally, the use of computational modelling may serve as a quick predictive tool to identify potential harmful interactions between dietary compounds and prescribed drugs.
引用
收藏
页数:13
相关论文
共 50 条
  • [31] Differential expression and activities of cytochrome P450 3A in the rat brain microsomes and mitochondria
    Alshammari, Nouf
    Chandrashekar, Devaraj Venkatapura
    Rashid, Mamunur
    Mehvar, Reza
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2023, 37 (02) : 359 - 368
  • [32] In vitro effects of tacrolimus on human cytochrome P450
    Lecointre, K
    Furlan, V
    Taburet, AM
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2002, 16 (06) : 455 - 460
  • [33] Effect of Crocetin on Cytochrome P450 Isoforms In Vitro
    Zhang, Jie
    Zhang, Bin
    Sun, Bin
    LATIN AMERICAN JOURNAL OF PHARMACY, 2021, 40 (09): : 2159 - 2163
  • [34] Inhibition of cytochrome P450 enhances the nephro- and hepatotoxicity of ochratoxin A
    Hassan, Reham
    Gonzalez, Daniela
    Hobloss, Zaynab
    Brackhagen, Lisa
    Myllys, Maiju
    Friebel, Adrian
    Seddek, Abdel-Latif
    Marchan, Rosemarie
    Cramer, Benedikt
    Humpf, Hans-Ulrich
    Hoehme, Stefan
    Degen, Gisela H.
    Hengstler, Jan G.
    Ghallab, Ahmed
    ARCHIVES OF TOXICOLOGY, 2022, 96 (12) : 3349 - 3361
  • [35] Thalidomide Increases Human Hepatic Cytochrome P450 3A Enzymes by Direct Activation of the Pregnane X Receptor
    Murayama, Norie
    van Beuningen, Rinie
    Suemizu, Hiroshi
    Guguen-Guillouzo, Christiane
    Shibata, Norio
    Yajima, Kanako
    Utoh, Masahiro
    Shimizu, Makiko
    Chesne, Christophe
    Nakamura, Masato
    Guengerich, F. Peter
    Houtman, Rene
    Yamazaki, Hiroshi
    CHEMICAL RESEARCH IN TOXICOLOGY, 2014, 27 (02) : 304 - 308
  • [36] Effects of gut microbiota on in vivo metabolism and tissue accumulation of cytochrome P450 3A metabolized drug: Midazolam
    Togao, Masao
    Kawakami, Koji
    Otsuka, Jun
    Wagai, Gaku
    Ohta-Takada, Yuki
    Kado, Shoichi
    BIOPHARMACEUTICS & DRUG DISPOSITION, 2020, 41 (07) : 275 - 282
  • [37] Effect of classic and atypical neuroleptics on cytochrome P450 3A (CYP3A) in rat liver
    Jacek Wójcikowski
    Anna Haduch
    Władysława A. Daniel
    Pharmacological Reports, 2012, 64 : 1411 - 1418
  • [38] The Structure-Activity Correlation on the Inhibitory Effects of Flavonoids on Cytochrome P450 3A Activity
    Tsujimoto, Masayuki
    Horie, Maya
    Honda, Hiroko
    Takara, Kohji
    Nishiguchi, Kohshi
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2009, 32 (04) : 671 - 676
  • [39] Reduced Duodenal Cytochrome P450 3A Protein Expression and Catalytic Activity in Patients With Cirrhosis
    McConn, D. J., II
    Lin, Y. S.
    Mathisen, T. L.
    Blough, D. K.
    Xu, Y.
    Hashizume, T.
    Taylor, S. L.
    Thummel, K. E.
    Shuhart, M. C.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 85 (04) : 387 - 393
  • [40] Deoxyschizandrin, a Naturally Occurring Lignan, Is a Specific Probe Substrate of Human Cytochrome P450 3A
    Wu, Jingjing
    Cao, Yunfeng
    Zhang, Yanyan
    Liu, Yong
    Hong, James Y.
    Zhu, Liangliang
    Ge, Guangbo
    Yang, Ling
    DRUG METABOLISM AND DISPOSITION, 2014, 42 (01) : 94 - 104